[Effects of nitroglycerin on exercise hemodynamics in patients with coronary heart disease under treatment with beta-blockers (mepindolol, oxprenolol) and a calcium-antagonist (fendiline) (author's transl)].
Nitroglycerin (0.8 mg p. o.) improves exercise hemodynamics in patients with coronary heart disease by normalizing left ventricular filling pressure and elevating volume output. Exercise heart rate and mean arterial blood pressure remain unchanged. Pretreatment with a beta-receptor-blocker (Mepindolol) and the combination of beta-receptor-blocker (Oxprenolol) with a calcium-antagonist (Fendiline) reduces the efficacy of nitroglycerin. The effects of the underlying treatment on the ventricular function curve shifting rightwards are not antagonized by nitroglycerin.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005275:Fendiline / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000627:therapeutic use*; D010096:Oxprenolol / Q000627:therapeutic use; D010627:Phenethylamines / Q000627:therapeutic use*; D010869:Pindolol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011292:Premedication
D000319:Adrenergic beta-Antagonists; D010627:Phenethylamines; C015340:mepindolol; D010096:Oxprenolol; D010869:Pindolol; D005996:Nitroglycerin; D005275:Fendiline
Der Einfluss von Nitroglyzerin auf die Belastungshämodynamik Koronarkranker bei Vorbehandlung mit Beta-Rezeptorenblockern (Mepindolol, Oxprenolol) und einem kalziumantagonisten (Fendilin).